Table 2 Adverse events (n = 71) during a median follow up of 36 months of TG therapy
|  | Grade 1 (mild) (n = 59) | Grade 2 (moderate) (n = 9) | Grade 3 (severe) (n = 3) | |||
|---|---|---|---|---|---|---|
General, neurological and psychological | Flu-like symptoms | 7 | – |  | – |  |
Blood, lymphatic and vascular disorders | Bone marrow suppression | 12 | Bone-marrow suppression | 2 | – |  |
Musculoskeletal and skin disorders | Alopecia | 5 | – |  | – |  |
Rash | 9 | |||||
Arthralgia/myalgia | 8 | |||||
Hepatobiliary disorders | DILI | 9 | DILI | 3 | Portal hypertension | 2 |
Gastrointestinal disorders | Nausea | 5 | Diarrhea | 1 | Pancreatitis | 1 |
Abdominal pain | 4 | |||||
Infections and infestations | – |  | EBV infection | 1 | Herpetic eye infection | 1 |
Neoplasm benign and malign | – |  | Melanoma | 1 | Diffuse large B-cell lymphoma | 1 |
Recurrent breast cancer | 1 | |||||